Compare Raymond James Financial, Inc. (RJF) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Raymond James Financial, Inc. is far larger — about 4× Spyre Therapeutics Inc. Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RJF | SYRE | |
|---|---|---|
Market Cap | $30.15B | $7.52B |
Volume | 980,106 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $181.18 | $108.92 |
52-Week Low | $140.89 | $22.18 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.02B | $6.52B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.25, down 0.88% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent earnings beats, revenue growth from $10.9B in 2022 to $13.84B in 2025, and robust profitability margins. Recent news highlights executive leadership changes and a declared $0.54 dividend payable in October 2026.
The stock presents a mixed outlook: attractive valuation multiples and analyst consensus price target of $178.50 suggest upside potential, but bearish technical indicators and rising expenses pose near-term risks. Investment appeal hinges on sustained earnings growth and management's execution amid market volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
